This indicates that the cells might maintain secretory competence and may explain the restoration of insulin secretion by sulfonylureas and glucagon-like peptide 1 (GLP-1) based treatments in type 2 diabetic patients [40]. The gene discussed is INS; the disease is type 2 diabetes mellitus.